Hua Medicine (the "Company", HKEx stock code: 2552) announced today that the Company and its wholly-owned subsidiary, Nanjing AscendRare Pharmaceutical Technology Co., Ltd.(AscendRare), presented a number of basic research findings at the 84th American Diabetes Association (ADA) Annual Scientific Sessions.
Hua Medicine (the "Company", HKEx stock code: 2552) announced today that its wholly owned subsidiary Nanjing AscendRare Pharmaceutical Technology Co., Ltd.
Hua Medicine (the "Company", HKEx: 2552.HK) announced that the Company has officially initiated its Phase I clinical trial of its 2nd generation glucokinase allosteric activator (2nd Gen GKA) in the United States, with the successful enrollment of the first patient.
The Company has achieved a certain milestone relating to the development of dorzagliatin and received RMB800 million non-refundable milestone payment. Collective cash balance of the Company was RMB1,461 million as of December 31, 2023.
Hua Medicine (HKEx:2552HK) announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for its 2nd generation glucokinase allosteric activator (2nd Gen GKA) to initiate a Phase I randomized, double-blinded, placebo-controlled, single-dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study in subjects with Type 2 diabetes mellitus (T2D) in the United States.
Hua Medicine (the "Company", HKEx: 2552.HK) announced today that HuaTangNing (華堂寧?) (dorzagliatin), its self-developed first-in-class glucokinase allosteric activator (GKA) for diabetes, has been successfully included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA).
Hua Medicine (HK:2552) today announced that it will present multiple research findings at the 25th Scientific Meeting of the Chinese Diabetes Society (CDS 2023).
Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").
Shanghai, 17 August 2023 – Sending Type 2 diabetes into remission is now a possibility thanks to Hua Medicine's HuaTangNing1 (華堂寧?) (dorzagliatin), as reported in a new published paper based on data from a 52-week study.